Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Drugs

Kalydeco (ivacaftor) Information

Kalydeco is approved for the treatment of CF in patients age six years and older who have the specific G551D mutation in the cystic fibrosis transmembrane regulator (CFTR) gene. In patients with the G551D mutation, Kalydeco helps the protein made by the CFTR gene function better and, as a result, improves lung function and other aspects of CF such as increasing weight gain.
 

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.

Regulatory History and Labeling from Drugs@FDA

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857

Page Last Updated: 07/15/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.